Literature DB >> 2539897

Severe eosinophilia associated with a malignant islet cell tumour.

J H Haldane1, H Kapoor, J Morris.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539897      PMCID: PMC1268980     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  Islet cell carcinoma of the pancreas.

Authors:  A L Cubilla; S I Hajdu
Journal:  Arch Pathol       Date:  1975-04

2.  Eosinophilopoietin. A circulating low molecular weight peptide-like substance which stimulates the production of eosinophils in mice.

Authors:  A A Mahmoud; M K Stone; R W Kellermeyer
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

Review 3.  Endocrine syndromes associated with pancreatic islet cell tumors.

Authors:  M E Levin
Journal:  Med Clin North Am       Date:  1968-03       Impact factor: 5.456

Review 4.  Investigations on eosinophilia. The influence of histamine, antigen-antibody complexes containing gamma-1 or gamma-2 globulins, foreign bodies (phagocytosis) and disrupted mast cells.

Authors:  W E Parish
Journal:  Br J Dermatol       Date:  1970-01       Impact factor: 9.302

5.  Malignant islet-cell tumour of the pancreas presenting with non-bacterial thrombotic endocarditis and eosinophilia.

Authors:  C P O'Boyle; J Dempsey; B Otridge; H Barniville
Journal:  Postgrad Med J       Date:  1981-07       Impact factor: 2.401

Review 6.  Eosinophil function.

Authors:  A E Butterworth; J R David
Journal:  N Engl J Med       Date:  1981-01-15       Impact factor: 91.245

Review 7.  Tumour-associated eosinophilia: a review.

Authors:  D Lowe; J Jorizzo; M S Hutt
Journal:  J Clin Pathol       Date:  1981-12       Impact factor: 3.411

  7 in total
  2 in total

1.  Hypereosinophilia in a horse with intestinal lymphosarcoma.

Authors:  W M Duckett; H K Matthews
Journal:  Can Vet J       Date:  1997-11       Impact factor: 1.008

2.  Hypereosinophilia in Solid Tumors-Case Report and Clinical Review.

Authors:  Ewa Zalewska; Łukasz Obołończyk; Krzysztof Sworczak
Journal:  Front Oncol       Date:  2021-03-24       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.